Reliable quantification of the antibody response to severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2) is highly relevant, eg, for identifying possible vaccine failure and …

Background In the context of the COVID-19 pandemic, numerous new serological test systems
for the detection of anti-SARS-CoV-2 antibodies rapidly have become available. However…

Neurofilament light chain (NfL) has emerged as a biomarker of neuroaxonal damage in
several neurologic conditions. With increasing availability of fourth-generation immunoassays …

The SARS-CoV-2 Omicron variant is characterized by substantial changes in the antigenic
structure of the Spike (S) protein. Therefore, antibodies induced by primary Omicron infection …

In an aging society, late‐life depression has become an increasing problem. There is evidence
that physical activity ameliorates depressive symptoms and increases the quality of life (…

… Perkmann T, Perkmann-Nagele N, Koller T, Mucher P, Radakovics A, Marculescu R, … Patrick
Mucher … Thomas Perkmann and Patrick Mucher contributed equally to this article. Author …

Objectives To investigate the comparability of WHO standard referenced commercial SARS-CoV-2
antibody tests over three doses of BNT162b2 vaccine and up to 14 months. Methods …

Epstein–Barr virus (EBV) reactivation may be involved in long-COVID symptoms, but
reactivation of other viruses as a factor has received less attention. Here we evaluated the …

Objective: To determine whether severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2)
antibody levels after the first dose of vaccine can predict the final antibody response, …

Background There is preliminary evidence that individuals with previous SARS‐CoV‐2
infections exhibit a more pronounced antibody response. However, these assumptions have not …